Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | FECH | P22830 | 1/20 | 0.51 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25998955 | 1.00 | EGFR (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25430973 | 1.00 | EGFR (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30576013 | 1.00 | EGFR (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25432582 | 1.00 | EGFR (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25433602 | 0.93 | ERBB2 (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25431144 | 0.93 | ERBB2 (0.51) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25431233 | 0.90 | ERBB2 (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL30575950 | 0.90 | ERBB2 (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25431872 | 0.90 | ERBB2 (0.48) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25430337 | 0.90 | ERBB2 (0.50) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4476211-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |